ATE426335T1 - Verfahren zur verbesserung der chemotherapie - Google Patents

Verfahren zur verbesserung der chemotherapie

Info

Publication number
ATE426335T1
ATE426335T1 AT00968797T AT00968797T ATE426335T1 AT E426335 T1 ATE426335 T1 AT E426335T1 AT 00968797 T AT00968797 T AT 00968797T AT 00968797 T AT00968797 T AT 00968797T AT E426335 T1 ATE426335 T1 AT E426335T1
Authority
AT
Austria
Prior art keywords
improving chemotherapy
cell proliferative
proliferative disorder
chemotherapy
improving
Prior art date
Application number
AT00968797T
Other languages
English (en)
Inventor
Michael Newman
William Dixon
Original Assignee
Taiji Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiji Biomedical Inc filed Critical Taiji Biomedical Inc
Application granted granted Critical
Publication of ATE426335T1 publication Critical patent/ATE426335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT00968797T 1999-10-08 2000-10-06 Verfahren zur verbesserung der chemotherapie ATE426335T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15832299P 1999-10-08 1999-10-08

Publications (1)

Publication Number Publication Date
ATE426335T1 true ATE426335T1 (de) 2009-04-15

Family

ID=22567591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968797T ATE426335T1 (de) 1999-10-08 2000-10-06 Verfahren zur verbesserung der chemotherapie

Country Status (7)

Country Link
EP (2) EP1221847B1 (de)
JP (1) JP2003511396A (de)
AT (1) ATE426335T1 (de)
AU (1) AU782401B2 (de)
CA (1) CA2382727A1 (de)
DE (1) DE60041880D1 (de)
WO (1) WO2001026467A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003216621A1 (en) 2002-04-10 2003-10-20 The Government Of The United States The Department Of Veterans Affairs Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
ES2497116T3 (es) 2002-08-19 2014-09-22 Lorus Therapeutics Inc. Imidazoles 2,4,5-trisustituidos y su uso como agentes antimicrobianos
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
CA2611032C (en) 2005-05-25 2012-01-17 Genesense Technologies Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
EP2454943B1 (de) 2010-11-23 2020-05-27 GEA Food Solutions Bakel B.V. Vorrichtung und Verfahren zur Herstellung eines Produkts mit Trennblättern
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
CN105764511B (zh) 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
EP3585378B1 (de) 2017-02-24 2022-04-27 BioActor B.V. Flavanonen zur verwendung bei der behandlung von visceralen hypersensitivität
KR20200096914A (ko) 2017-10-30 2020-08-14 압토스 바이오사이언시스 인코포레이티드 암 치료용 아릴 이미다졸
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors
WO2025119974A1 (en) 2023-12-04 2025-06-12 Bioactor Bv Naringin or naringenin for improving sleep quality

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5756527A (en) * 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators

Also Published As

Publication number Publication date
EP1221847A1 (de) 2002-07-17
DE60041880D1 (de) 2009-05-07
WO2001026467A1 (en) 2001-04-19
EP1221847B1 (de) 2009-03-25
EP1221847A4 (de) 2006-03-22
CA2382727A1 (en) 2001-04-19
AU7866100A (en) 2001-04-23
JP2003511396A (ja) 2003-03-25
EP2064951A1 (de) 2009-06-03
AU782401B2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
DE122011100040I2 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.
EP1622616A4 (de) Hemmer der akt aktivität
DE60041880D1 (de) Verfahren zur verbesserung der chemotherapie
EP1631548A4 (de) Hemmer der akt aktivität
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
DK1159279T3 (da) 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
EE9500034A (et) Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine
BRPI0116967B8 (pt) derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
DK1056704T3 (da) Antitumormidler
ES2013403A6 (es) Procedimiento para preparar derivados de cefem.
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
EP1627635A3 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen
WO2004075858A3 (en) Flavone acetic acid analogs and methods of use thereof
DE60113838D1 (de) Derivate von triterpen-säuren
AR026222A1 (es) Compuestos derivados de acido antranilico
MXPA05012360A (es) Derivados de benzotiazol como ligandos receptores de adenosina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties